Bristol Myers Bonds

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Report: 6th of August 2020  

Bristol Myers financial leverage is the degree to which the firm utilises its fixed-income securities. Companies with high leverage are usually considered to be at financial risk. Bristol Myers Squibb financial risk is the risk to Bristol Myers stockholders that is caused by an increase in debt. In other words with a high degree of financial leverage come high interest payments which usually reduces Earnings Per Share (EPS). Continue to the analysis of Bristol Myers Fundamentals Over Time.

Search Bonds

 
Refresh
Total Debt is likely to grow to about 50.4 B in 2020. Debt Current is likely to grow to about 3.6 B in 2020

  Bristol Myers Quarterly Debt to Equity Ratio

Bristol Myers Bond Ratings

Total Macroaxis Rating
Very Firm
Average S&P Rating
A+
Piotroski F Score
5  Healthy

Bristol Myers Squibb Debt to Cash Allocation

The company has 47.53 B in debt with debt to equity (D/E) ratio of 0.95, which is OK given its current industry classification. Bristol Myers Squibb has a current ratio of 1.63, which is typical for the industry and considered as normal.

Bristol Myers Inventories Over Time

 

Bristol Myers Corporate Bonds Issued

Issue DateMaturityCouponRef CouponS&P Rating
110122AA6 7.15%06/04/199306/15/20237.152.25
A+
110122AB4 6.8%11/15/199611/15/20266.82.25
A+
110122AC2 6.875%08/12/199708/01/20976.8753.0
A+
110122AP3 5.875%11/20/200611/15/20365.8755.375
A+
110122AQ1 6.125%05/01/200805/01/20386.1255.375
A+
110122AS7 0.875%07/31/201208/01/20170.8750.875
A+
110122AT5 2.0%07/31/201208/01/20222.02.0
A+
110122AU2 3.25%07/31/201208/01/20423.253.0
A+
110122AV0 1.75%10/31/201303/01/20191.751.5
A+
110122AW8 3.25%10/31/201311/01/20233.252.25
A+
110122AX6 4.5%10/31/201303/01/20444.53.0
A+
110122AR9 5.45%05/01/200805/01/20185.451.0
A+

Bristol Myers Squibb Historical Liabilities

Understending Bristol Myers Use of Financial Leverage

Bristol Myers financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures the total debt position of Bristol Myers, including all of Bristol Myers's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Bristol Myers assets, the company is considered highly leveraged. Understanding the composition and structure of overall Bristol Myers debt and outstanding corporate bonds gives a good idea as to how risky the capital structure of a business and if it is worth investing in it. Please read more on our technical analysis page.
Last ReportedProjected for 2020
Total Debt46.7 B50.4 B
Debt Current3.3 B3.6 B
Debt Non Current43.4 B46.8 B
Issuance Repayment of Debt Securities17.7 B19 B
Long Term Debt to Equity 0.84  0.91 
Debt to Equity Ratio 1.52  1.57 
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 30000 people.

Current Sentiment - BMY

Bristol Myers Squibb Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Bristol Myers Squibb. What is your opinion about investing in Bristol Myers Squibb? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Bristol Myers Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bristol Myers and Gilead Sciences. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to the analysis of Bristol Myers Fundamentals Over Time. Please also try Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page